We are live on ! Find out more
KALV icon

KalVista Pharmaceuticals

Delisted

KALV was delisted on the 10th of June, 2026.

18 hedge funds and large institutions have $52.2M invested in KalVista Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more capital inflows, than outflows

Capital inflows: $3.76M | Capital outflows: $1.29M

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

3.57% more ownership

Funds ownership: 75.89% → 79.46% (+3.6%)

0% more funds holding

Funds holding: 18 → 18 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
18
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
1
Increased
5
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KALV Hedge Fund Activity: Q3 2017 in Review

18 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2017, worth a combined $52.2M — down 3.4% from $54.1M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of KALV and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.

The largest buyer was Vivo Capital, opening a new position worth an estimated $2.14M. The largest seller was Novo Holdings A/S, cutting an estimated $1.26M.

  • 18 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $52.2M of KalVista Pharmaceuticals stock for Q3 2017, down 3.4% quarter-over-quarter.
  • 1 fund opened new KalVista Pharmaceuticals positions in Q3 2017 and 2 closed out, a net change of -1 holder.
  • The largest KalVista Pharmaceuticals buyer in Q3 2017 was Vivo Capital, an estimated $2.14M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2017 was Novo Holdings A/S, an estimated $1.26M sold.

Based on aggregated 13F filings for Q3 2017.